Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide for First-Line Treatment of Chronic GvHD
NCT02966301Phase 2Completed
- Sponsor
- Medsenic
- Start
- Dec 2016
- Primary completion
- Jun 2020
- Modality
- DNA Intercalators/Alkylators
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide in chronic graft-versus-host disease (cGVHD), sponsored by Medsenic. Primary endpoint: Overall Response Rate at 6 months. Started Dec 2016; status: completed.
02
Drugs
arsenic trioxide
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT02966301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02966301.